Drug Profile
Venetoclax - AbbVie/Genentech
Alternative Names: A-1195425.0; ABT 0199; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO; VenclyxtoLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
- Developer AbbVie; Celgene Corporation; Dana-Farber Cancer Institute; Eli Lilly and Company; Emory University; Genentech; Janssen Research & Development; M. D. Anderson Cancer Center; Merck & Co; Nantes University Hospital; National Cancer Institute (USA); Nordic Lymphoma Group; Pharmacyclics; Roche; Syros Pharmaceuticals; University Health Network
- Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia
- Registered Acute myeloid leukaemia
- Phase III Mantle-cell lymphoma; Myelodysplastic syndromes
- Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Phase I/II Chronic myelomonocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
- Phase I B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Cancer; Haematological malignancies; Non-small cell lung cancer; Small cell lung cancer
- No development reported Systemic lupus erythematosus
Most Recent Events
- 15 Feb 2024 Discontinued - Phase-I for Myelodysplastic syndromes (Combination therapy, Newly diagnosed, Second-line therapy or greater) in Australia (PO) (Roche pipeline, February 2024)
- 15 Feb 2024 Discontinued - Phase-I for Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) in Germany (PO) (Roche pipeline, February 2024)
- 15 Feb 2024 Roche plans to file regulatory application for myelodysplastic syndrome (Newly diagnosed, Combination therapy) in 2025 (Roche pipeline, February 2024)